Cargando…
SAT-272 A Phase 2 Comparison of a Stable Liquid Glucagon to Placebo for the Treatment of Congenital Hyperinsulinism
OBJECTIVE: A novel ready-to-use stable liquid Glucagon (CSIG; Xeris Pharmaceuticals) delivered continuously through a patch pump, was evaluated for the treatment of congenital hyperinsulinism (CHI). METHOD: This was a Phase 2, randomized, placebo-controlled, double-blind trial with open-la...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552081/ http://dx.doi.org/10.1210/js.2019-SAT-272 |